Camber Pharmaceuticals – Recall of losartan

- On February 28, 2019, the FDA announced the voluntary, consumer-level recall of several lots of Camber Pharmaceuticals' losartan tablets due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs.

- NMBA is a potential human carcinogen. To date, Camber has not received any reports of adverse events related to this recall.

    — Refer to the FDA site for updates regarding angiotensin II receptor blocker recalls.

- The recalled products are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Losartan Tablets 25 mg	31722-0700-90	LOP17026B (9/2019); LOP17050 (9/2019); LOP17051 (9/2019); LOP17052 (9/2019); LOP17053 (9/2019); LOP17061 (10/2019); LOP18035 (12/2019); LOP18036 (12/2019)
	31722-0700-05	LOP17026 (9/2019)
	31722-0700-10	LOP17006 (5/2019); LOP17025 (9/2019); LOP17068 (10/2019); LOP18037 (12/2019); LOP18038 (12/2019); LOP18039 (12/2019); LOP18057 (1/2020)
Losartan Tablets 50 mg	31722-0701-30	LOP17028C (9/2019); LOP17064A (11/2019)
	31722-0701-90	LOP17027 (9/2019); LOP17063 (11/2019); LOP17093 (11/2019); LOP17094 (12/2019); LOP17095 (12/2019); LOP17097A (12/2019); LOP17105 (12/2019); LOP17107 (12/2019)
	31722-0701-10	LOP17004 (12/2019); LOP17028B (9/2019); LOP17048 (10/2019); LOP17049 (10/2019); LOP17056 (11/2019); LOP17073 (11/2019);

Continued . . .

		LOP17074 (11/2019); LOP17076 (11/2019); LOP17096 (12/2019); LOP18077A (2/2020); LOP18078 (2/2020); LOP18079 (2/2020); LOP18080 (2/2020); LOP18081 (3/2020); LOP18084 (3/2020); LOP18095 (3/2020); LOP18096 (3/2020)
Losartan Tablets 100 mg	31722-0702-30	LOP17011 (8/2019); LOP17087 (11/2019)
	31722-0702-90	LOP17012 (8/2019); LOP17013 (8/2019); LOP17042 (10/2019); LOP17043 (10/2019); LOP17044 (11/2019); LOP17045 (11/2019); LOP18024 (12/2019); LOP18025 (12/2019); LOP18026 (12/2019); LOP18027 (12/2019); LOP18028 (12/2019); LOP18029 (12/2019); LOP18030 (12/2019)
	31722-0702-10	LOP17005 (5/2019); LOP17014 (8/2019); LOP17016 (9/2019); LOP17023 (9/2019); LOP17083 (10/2019); LOP17084 (11/2019); LOP17085 (11/2019); LOP17086 (11/2019); LOP18021 (12/2019); LOP18022 (12/2019); LOP18023 (12/2019); LOP18031 (12/2019); LOP18032 (12/2019); LOP18033 (12/2019); LOP18050 (12/2019); LOP18051 (12/2019); LOP18109 (3/2020); LOP18111 (3/2020); LOP18122 (6/2020); LOP18123 (6/2020); LOP18124 (6/2020); LOP18125 (6/2020); LOP18126 (6/2020); LOP18127 (6/2020); LOP18128 (6/2020); LOP18129 (6/2020); LOP18130 (6/2020); LOP18131C (6/2020); LOP18133 (6/2020)

- Losartan tablets are used for the treatment of hypertension (HTN); to reduce the risk of stroke in patients with HTN and left ventricular hypertrophy; and for the treatment of diabetic nephropathy with

an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of HTN.

- Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are on losartan should continue taking their medication, as the risk of harm to a patient's health may be higher if the treatment is stopped immediately without any alternative treatment.

- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled losartan.

- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.

- For more information regarding this recall, contact Camber Pharmaceuticals at **1-866-495-1995**.